|
|
|
|
|
by disgruntledphd2
4503 days ago
|
|
OK, lets take this in order. Hrobjarrtsson and Goetzche's review actually undermines your point around there being many placebo effects (which is the approach taken by Benedetti), as they modelled wildly different clinical trials (the inclusion criteria were simply possessing both a placebo and no-treatment arm). Furthermore, Meissner et al 2007 re-analysed those studies and found large effects where the outcome could be mediated by nervous system, and very low effects where there was no direct nervous system link. Additionally, uncertain expectations (you may receive a drug) are given in clinical trials and Vase (2002) found that placebo effect sizes were much smaller in this context than they are when placebos are deceptively administered (this is a potent painkiller) (as they normally are in clinical practice and experimental research) (c.f. Kirsch & Wiexel 1998, Amanzio et al 2001). Also certain vs uncertain expectations are associated with differential amounts of dopamine release, which has been associated with response to placebo (Scott et al 2007, DeLa Fuente-Fernandez, 2002, 2004). I agree with many of your comments around this paper, and essentially it was only published because Kaptchuk and Kirsch are two of the leading names in the non-clinical field. And the papers from 2010, and has been getting this treatment for a while.... |
|
Though I disagree that Hróbjartsson et al undermines the notion of many placebo effects.. or maybe I don't, depending on our definition of placebo effect.
If we define "placebo effect" as any clinically significant change observed in the placebo wing of a clinical trial, there are many placebo effects. As I mentioned before, regression to the mean, natural history of the disease, experimenter effect, and so on.
Alternatively, we could define it as any clinically significant change observed in the placebo wing of a clinical trial which is not also observed in a no treatment wing. This would eliminate things like regression to the mean and arguably leave behind only a "true" placebo effect. Though even here, we have to account for bias (and perhaps even classical conditioning?) I wonder how much placebo effect is left if these are controlled for?
Within the context of analysing trial data, it is the former definition we are interested in. But within the context of discussing "the placebo effect" as a standalone phenomenon, I'd argue the latter definition is more useful.
Unfortunately, as most trials don't have no treatment arms, any clinically significant changes observed in the placebo arm are chalked up to "the placebo effect", especially by the media (though sometimes by clinicians), even when there is good reason to think many of those same changes would have been observed under no treatment. Which IMHO leads to a distorted view of the clinical relevance of the placebo effect outside the context of a clinical trial. Especially as the placebo effect appears to have a reputation as a bizarre mind-over-matter affair.